ZFIN ID: ZDB-FISH-151105-25
Fish name: gz32Tg
Genotype: gz32Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by gz32Tg
Human Disease Conditions Citations
hepatocellular carcinoma chemical treatment by environment: doxycycline Li et al., 2019
chemical treatment by environment: doxycycline Yang et al., 2017
chemical treatment by environment: doxycycline Li et al., 2017
chemical treatment: doxycycline Yan et al., 2017
chemical treatment: doxycycline Yan et al., 2017
chemical treatment: doxycycline monohydrate Yan et al., 2015
chemical treatment: doxycycline monohydrate Chew et al., 2014
GENE EXPRESSION
Gene expression in gz32Tg
RNA expression
Expressed Gene Structure Conditions Figures
col1a1b chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
csf1a chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
cxcl8a chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
cyp11a1 chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
cyp17a1 chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
il12a chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
lama5 chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
snai1a chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
snai2 chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
tgfb1a chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
tnfa chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
tph1b chemical treatment by environment: doxycycline Fig. 3 with image from Yang et al., 2017
vegfab chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
vegfc chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
PHENOTYPE
Phenotype in gz32Tg
Phenotype Conditions Figures
female organism hematopoietic stem cell ab5-pcna labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
female organism hematopoietic stem cell ab5-pcna labeling increased amount, abnormal chemical treatment by environment: serotonin, chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
female organism hepatocellular adenoma increased amount, abnormal chemical treatment: doxycycline Fig. 1Fig. 6 from Yan et al., 2017
female organism hepatocellular adenoma increased amount, exacerbated chemical treatment: cortisol, chemical treatment: doxycycline Fig. 6 from Yan et al., 2017
female organism hepatocellular carcinoma increased amount, exacerbated chemical treatment: cortisol, chemical treatment: doxycycline Fig. 6 from Yan et al., 2017
female organism hepatocyte hyperplastic, abnormal chemical treatment: doxycycline Fig. 1Fig. 6 from Yan et al., 2017
female organism hepatocyte hyperplastic, exacerbated chemical treatment: cortisol, chemical treatment: doxycycline Fig. 6 from Yan et al., 2017
female organism hepatocyte cyp11a1 expression increased amount, abnormal chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
female organism hepatocyte tgfb1a expression increased amount, abnormal chemical treatment: cortisol, chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
female organism hepatocyte cxcl8a expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte vegfab expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte snai2 expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte vegfc expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte col1a1b expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte cyp17a1 expression increased amount, abnormal chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
female organism hepatocyte lama5 expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte csf1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte snai1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte tnfa expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte il12a expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
female organism hepatocyte tgfb1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
female organism liver hyperplastic, abnormal standard conditions Fig. 1 with image from Yang et al., 2017
female organism liver increased size, abnormal chemical treatment by environment: serotonin, chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
female organism liver increased size, abnormal chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
hepatocyte cell outer membrane ab13-ctnnb labeling decreased amount, abnormal chemical treatment by environment: doxycycline Fig. 4 with image from Li et al., 2017
hepatocyte cell outer membrane ab2-cdh1 labeling decreased amount, abnormal chemical treatment by environment: doxycycline Fig. 2 with imageFig. 4 with image from Li et al., 2017
hepatocyte cell population proliferation increased occurrence, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
hepatocyte nucleolus increased amount, abnormal chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte nucleolus increased amount, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 6 with image from Yan et al., 2017
hepatocyte nucleolus increased amount, abnormal chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte nucleus size, abnormal chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte nucleus size, abnormal chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte nucleus size, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 6 with image from Yan et al., 2017
hepatocyte vacuole increased amount, abnormal chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte vacuole increased amount, abnormal chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte vacuole increased amount, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 6 with image from Yan et al., 2017
liver ab6-pcna labeling amount, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 4 with image from Yan et al., 2017
liver circular, abnormal chemical treatment: doxycycline Fig. 1 with image from Yan et al., 2017
liver hyperplastic, abnormal chemical treatment by environment: doxycycline Fig. 1 with image from Li et al., 2017
liver hyperplastic, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 6 with image from Yan et al., 2017
liver hyperplastic, abnormal chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
liver hyperplastic, abnormal chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
liver hyperplastic, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 6 with image from Yan et al., 2017
liver ab5-pcna labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 2 with imageFig. 4 with imageFig. 5 with image from Li et al., 2017
liver ab6-pcna labeling increased amount, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 4 with image from Yan et al., 2017
liver ab6-pcna labeling increased amount, abnormal chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
liver ab6-pcna labeling increased amount, abnormal chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment: doxycycline monohydrate Fig. 4 from Chew et al., 2014
liver increased size, abnormal chemical treatment by environment: doxycycline Fig. 6 with image from Li et al., 2017
liver increased size, abnormal chemical treatment by environment: doxycycline, chemical treatment by environment: 11-oxotestosterone Fig. 6 with image from Li et al., 2017
liver increased size, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
liver increased size, abnormal chemical treatment: doxycycline, chemical treatment: GANT61 Fig. 3 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 3 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment: doxycycline, chemical treatment: cardionogen-1 Fig. 2 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 2 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment: doxycycline Fig. 1 with imageFig. 2 with imageFig. 3 with image from Yan et al., 2017
liver increased size, ameliorated chemical treatment by environment: doxycycline, chemical treatment by environment: 17beta-estradiol Fig. 6 with image from Li et al., 2017
liver neoplastic, abnormal chemical treatment by environment: doxycycline Fig. 1 with imageFig. 2 with imageFig. 3 with image from Li et al., 2017
liver neoplastic, abnormal chemical treatment: doxycycline monohydrate Fig. 7 from Chew et al., 2014
liver neoplastic, abnormal chemical treatment by environment: doxycycline Fig. 4 with imageFig. 6 with image from Li et al., 2019
liver neoplastic, abnormal chemical treatment: doxycycline Fig. 1Fig. 6 from Yan et al., 2017
liver neoplastic, ameliorated chemical treatment: mifepristone Fig. 6 from Yan et al., 2017
liver neoplastic, exacerbated chemical treatment by environment: 11-oxotestosterone, chemical treatment by environment: doxycycline Fig. 6 with image from Li et al., 2019
liver neoplastic, exacerbated chemical treatment: cortisol, chemical treatment: doxycycline Fig. 6 from Yan et al., 2017
liver size, ameliorated chemical treatment: doxycycline, chemical treatment: orantinib Fig. 1 with image from Yan et al., 2017
liver size, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 1 with image from Yan et al., 2017
liver apoptotic process increased occurrence, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 5 with image from Yan et al., 2017
liver apoptotic process increased occurrence, abnormal chemical treatment: doxycycline Fig. 5 with image from Yan et al., 2017
liver apoptotic process occurrence, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 5 with image from Yan et al., 2017
liver apoptotic process occurrence, ameliorated chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 5 with image from Yan et al., 2017
liver cell population proliferation increased occurrence, abnormal chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
liver cell population proliferation increased occurrence, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 4 with image from Yan et al., 2017
liver cell population proliferation increased occurrence, abnormal chemical treatment by environment: doxycycline Fig. 2 with imageFig. 6 with image from Li et al., 2017
liver cell population proliferation increased occurrence, abnormal chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
liver cell population proliferation increased occurrence, abnormal chemical treatment by environment: doxycycline Fig. 5 with imageFig. 6 with image from Li et al., 2019
liver cell population proliferation increased occurrence, ameliorated chemical treatment by environment: doxycycline, chemical treatment by environment: 17beta-estradiol Fig. 6 with image from Li et al., 2017
liver cell population proliferation increased occurrence, exacerbated chemical treatment by environment: 11-oxotestosterone, chemical treatment by environment: doxycycline Fig. 6 with image from Li et al., 2019
liver cell population proliferation increased occurrence, exacerbated chemical treatment by environment: doxycycline, chemical treatment by environment: 11-oxotestosterone Fig. 6 with image from Li et al., 2017
liver cell population proliferation increased process quality, abnormal chemical treatment: doxycycline monohydrate Fig. 2Fig. 4Fig. 7 from Chew et al., 2014
liver cell population proliferation occurrence, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 4 with image from Yan et al., 2017
liver cortisol amount, ameliorated chemical treatment: doxycycline, chemical treatment: 17beta-estradiol Fig. 4 from Yan et al., 2017
liver cortisol amount, ameliorated chemical treatment: doxycycline, chemical treatment: U0126 Fig. 4 from Yan et al., 2017
liver cortisol increased amount, abnormal chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
liver hepatocellular adenoma increased amount, abnormal chemical treatment by environment: doxycycline Fig. 4 with imageFig. 6 with image from Li et al., 2019
liver hepatocellular adenoma increased amount, exacerbated chemical treatment by environment: 11-oxotestosterone, chemical treatment by environment: doxycycline Fig. 6 with image from Li et al., 2019
liver hepatocellular carcinoma increased amount, abnormal chemical treatment by environment: doxycycline Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 6 with image from Li et al., 2017
liver hepatocellular carcinoma increased amount, abnormal chemical treatment by environment: doxycycline Fig. 4 with imageFig. 6 with image from Li et al., 2019
liver hepatocellular carcinoma increased amount, ameliorated chemical treatment by environment: doxycycline, chemical treatment by environment: 17beta-estradiol Fig. 6 with image from Li et al., 2017
liver hepatocellular carcinoma increased amount, exacerbated chemical treatment by environment: 11-oxotestosterone, chemical treatment by environment: doxycycline Fig. 6 with image from Li et al., 2019
liver hepatocellular carcinoma increased amount, exacerbated chemical treatment by environment: doxycycline, chemical treatment by environment: 11-oxotestosterone Fig. 6 with image from Li et al., 2017
liver hepatocellular carcinoma increased occurrence, abnormal chemical treatment: doxycycline monohydrate Fig. 4Fig. 7 from Chew et al., 2014
liver hepatocyte condensed, abnormal standard conditions Fig. 1 with image from Yang et al., 2017
liver hepatocyte proliferative, abnormal standard conditions Fig. 1 with image from Yang et al., 2017
liver neoplasm increased size, abnormal chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
liver neoplasm increased size, abnormal chemical treatment by environment: 4-chloro-L-phenylalanine, chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
liver neoplasm increased size, abnormal chemical treatment by environment: serotonin, chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
male organism decreased life span, abnormal chemical treatment by environment: doxycycline Fig. 4 with image from Li et al., 2019
male organism hematopoietic stem cell Ab14-gfap labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 2 with image from Yang et al., 2017
male organism hematopoietic stem cell ab5-pcna labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
male organism hematopoietic stem cell ab-smad2 labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 2 with image from Yang et al., 2017
male organism hematopoietic stem cell ab1-casp3 labeling increased amount, abnormal chemical treatment by environment: 4-chloro-L-phenylalanine, chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
male organism hepatocellular adenoma increased amount, abnormal chemical treatment: doxycycline Fig. 1Fig. 6 from Yan et al., 2017
male organism hepatocellular adenoma increased amount, ameliorated chemical treatment: mifepristone Fig. 6 from Yan et al., 2017
male organism hepatocellular carcinoma increased amount, abnormal chemical treatment: doxycycline Fig. 1Fig. 6 from Yan et al., 2017
male organism hepatocellular carcinoma increased amount, ameliorated chemical treatment: mifepristone Fig. 6 from Yan et al., 2017
male organism hepatocyte tgfb1a expression amount, ameliorated chemical treatment: mifepristone Fig. 4 from Yan et al., 2017
male organism hepatocyte tnfa expression decreased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte hyperplastic, abnormal chemical treatment: doxycycline Fig. 1Fig. 6 from Yan et al., 2017
male organism hepatocyte hyperplastic, ameliorated chemical treatment: mifepristone Fig. 6 from Yan et al., 2017
male organism hepatocyte snai2 expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte tph1b expression increased amount, abnormal chemical treatment by environment: doxycycline Fig. 3 with image from Yang et al., 2017
male organism hepatocyte vegfc expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte lama5 expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte snai1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte il12a expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte csf1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte tgfb1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
male organism hepatocyte cyp11a1 expression increased amount, abnormal chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
male organism hepatocyte cxcl8a expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte vegfab expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism hepatocyte cyp17a1 expression increased amount, abnormal chemical treatment: doxycycline Fig. 4 from Yan et al., 2017
male organism hepatocyte col1a1b expression increased amount, abnormal chemical treatment: doxycycline Fig. 1 from Yan et al., 2017
male organism liver adenomatous, abnormal standard conditions Fig. 1 with image from Yang et al., 2017
male organism liver ab2-col1 labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 1 with imageFig. 5 with image from Yang et al., 2017
male organism liver ab-smad2 labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 7 with image from Yang et al., 2017
male organism liver ab1-serotonin labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 3 with imageFig. 7 with image from Yang et al., 2017
male organism liver ab1-casp3 labeling increased amount, abnormal chemical treatment by environment: 4-chloro-L-phenylalanine, chemical treatment by environment: doxycycline Fig. 6 with image from Yang et al., 2017
male organism liver ab5-pcna labeling increased amount, abnormal chemical treatment by environment: doxycycline Fig. 1 with imageFig. 7 with image from Yang et al., 2017
male organism liver increased size, abnormal standard conditions Fig. 1 with image from Yang et al., 2017
male organism liver increased size, abnormal chemical treatment by environment: doxycycline Fig. 4 with image from Yang et al., 2017
male organism macrophage cyp11a1 expression amount, ameliorated chemical treatment: doxycycline, chemical treatment: 17beta-estradiol Fig. 4 from Yan et al., 2017
male organism macrophage cyp11a1 expression amount, ameliorated chemical treatment: doxycycline, chemical treatment: U0126 Fig. 4 from Yan et al., 2017
male organism macrophage cyp17a1 expression amount, ameliorated chemical treatment: doxycycline, chemical treatment: U0126 Fig. 4 from Yan et al., 2017
male organism macrophage cyp17a1 expression amount, ameliorated chemical treatment: doxycycline, chemical treatment: 17beta-estradiol Fig. 4 from Yan et al., 2017
whole organism decreased life span, abnormal chemical treatment: doxycycline monohydrate Fig. 7 from Chew et al., 2014
whole organism decreased life span, abnormal chemical treatment by environment: doxycycline Fig. 3 with image from Li et al., 2017

CITATIONS  (7)